Polygenic Risk Scores Explained: What Your DNA Really Says About Disease Risk

What if a single DNA test could reveal hidden risk for a heart attack - even if your cholesterol, blood pressure, and lifestyle all look perfect?

That's exactly what polygenic risk scores (PRS) promise to do. Unlike traditional genetic tests that look for one dramatic mutation (like BRCA1 for breast cancer), a polygenic risk score adds up the tiny effects of thousands - sometimes millions - of genetic variants scattered across your genome. The result is a single number that estimates your inherited predisposition to a specific disease. It's not a diagnosis. It's not destiny. But for conditions like coronary artery disease, type 2 diabetes, and breast cancer, it can reveal risk that no blood test or family history questionnaire would ever catch (Khera et al., 2018).

What Is a Polygenic Risk Score?

Most common diseases aren't caused by a single gene. Heart disease, diabetes, Alzheimer's, obesity - these conditions are polygenic, meaning they're influenced by many genes working together, each contributing a small nudge toward higher or lower risk (Visscher et al., 2017).

A polygenic risk score captures this complexity. Here's how it works:

• Scientists run massive studies called genome-wide association studies (GWAS) that scan the DNA of hundreds of thousands of people, comparing those with a disease to those without (Uffelmann et al., 2021).
• GWAS identifies specific locations in DNA - called single nucleotide polymorphisms (SNPs, pronounced "snips") - where having one letter instead of another slightly increases or decreases disease risk.
• A polygenic risk score takes all those SNPs, weights each one by its effect size, and adds them up into a single number (Choi et al., 2020).

Think of it like a credit score for disease risk. No single factor determines your score - it's the combination of thousands of small inputs that paints the picture.

How Many Variants Are We Talking About?

The numbers are staggering. Modern polygenic risk scores for coronary artery disease incorporate over 6 million genetic variants (Khera et al., 2018). For type 2 diabetes, scores can include over 1 million SNPs. Even traits like height involve thousands of contributing loci (Yengo et al., 2022).

Each individual variant might shift your risk by a fraction of a percent. But when millions of these tiny effects align in the same direction, they can add up to a substantial increase - or decrease - in disease probability.

What Can Polygenic Risk Scores Predict?

The strongest evidence exists for a handful of common diseases:

• Coronary artery disease: In a landmark 2018 study of over 400,000 UK Biobank participants, Khera and colleagues found that 8% of the population had a polygenic risk score placing them at three-fold or greater risk of coronary artery disease - equivalent to the risk conferred by rare monogenic mutations in genes like LDLR, but affecting 20 times more people (Khera et al., 2018).
• Breast cancer: Polygenic risk scores can identify women in the top 1% of genetic risk who face a lifetime breast cancer risk of approximately 33%, compared to 12% for the average woman (Mavaddat et al., 2019).
• Type 2 diabetes: Individuals in the top 10% of polygenic risk have roughly twice the risk of developing type 2 diabetes compared to those in the middle of the distribution (Mars et al., 2020).
• Atrial fibrillation, inflammatory bowel disease, and Alzheimer's disease are among other conditions where PRS shows meaningful risk stratification (Wray et al., 2021).

The key insight: many people who go on to have heart attacks or develop diabetes would never have been flagged as "high risk" by traditional screening. Their cholesterol might be fine. Their blood sugar normal. But their DNA tells a different story.

What Your Polygenic Risk Score Actually Means

Here's where things get nuanced. A polygenic risk score is a relative measure, not an absolute prediction. It tells you where you fall compared to a reference population - typically reported in percentiles:

• Top 1–5%: Substantially elevated genetic risk. Often comparable to having a single high-risk mutation. Warrants proactive screening and possibly earlier intervention.
• Top 5–20%: Moderately elevated risk. Worth discussing with a physician, especially if other risk factors (smoking, family history, obesity) are present.
• Middle 20–80%: Average genetic risk. Disease prevention follows standard guidelines.
• Bottom 20%: Lower-than-average genetic risk. Not zero risk - lifestyle, environment, and other factors still matter.

A high polygenic risk score does not mean you will definitely get the disease. A low score does not mean you're immune. Your genes set the stage, but diet, exercise, stress, sleep, and environmental exposures write much of the script (Torkamani et al., 2018).

The Diversity Problem: A Critical Limitation

There is a serious equity issue baked into current polygenic risk scores. Approximately 86% of all GWAS participants have been of European descent (Martin et al., 2019). This means polygenic risk scores are significantly less accurate for people of African, Asian, Hispanic, and Indigenous ancestry.

A 2023 study in Nature confirmed that PRS accuracy drops in a predictable gradient as genetic ancestry diverges from the European populations used in training data (Ding et al., 2023). For some conditions, the predictive power in African-ancestry populations is less than half what it is for European-ancestry populations.

This isn't just an academic concern - it risks widening health disparities if polygenic scores are rolled out clinically without addressing this gap (Martin et al., 2019). Efforts like the All of Us Research Program and the expansion of biobanks in Africa and Asia aim to close this divide, but progress takes time.

If you're using a direct-to-consumer DNA test to estimate polygenic risk, ask: Was this score validated in a population that looks like me?

How Polygenic Risk Scores Fit Into Clinical Care

As of 2026, polygenic risk scores are not yet standard in most clinical settings - but they're getting closer. A 2024 Nature Medicine study validated polygenic risk scores for ten chronic diseases across diverse U.S. populations, demonstrating that PRS can meaningfully improve risk prediction when combined with traditional clinical factors (Lennon et al., 2024).

Several healthcare systems are piloting PRS integration:

• Mass General Brigham in Boston has begun incorporating coronary artery disease PRS into cardiology workflows.
• The UK's NHS is evaluating PRS for breast cancer screening stratification.
• Geisinger Health System uses PRS alongside clinical genomics for proactive patient outreach.

The consensus among researchers is that PRS works best not as a standalone tool, but as one layer added to existing risk assessment - alongside family history, biomarkers, imaging, and lifestyle factors (Polygenic Risk Score Task Force, 2021).

What You Can Do With This Information

If you've had DNA testing done and want to understand your polygenic risk, here are practical steps:

• Upload your raw DNA data to a service like GenomeInsight that analyzes genetic variants associated with common diseases. We examine over 500 variants across health risks, pharmacogenomics, and inherited conditions.
• Talk to your doctor. A high polygenic risk score for heart disease might justify earlier lipid panels, coronary calcium scoring, or statin therapy - even if your traditional risk factors look normal.
• Don't panic over a single number. PRS is probabilistic, not deterministic. A score in the 90th percentile for type 2 diabetes means elevated risk, not a foregone conclusion. Lifestyle modifications - exercise, diet, weight management - remain powerful interventions regardless of your genetic risk (Khera et al., 2019).
• Consider family implications. Polygenic risk is inherited. If you have a high score, your biological relatives likely share elevated risk. This information can prompt earlier screening for siblings, parents, or children.
• Stay informed. PRS algorithms improve rapidly as GWAS datasets grow larger and more diverse. Your risk estimate today may be refined as the science advances. Subscribe to our newsletter for updates on genetic health research.

Key Takeaways

• A polygenic risk score sums up the effects of thousands to millions of genetic variants to estimate disease risk - it's like a genetic weather forecast.
• PRS can identify people at 3x or higher risk for heart disease, breast cancer, and other conditions who would otherwise be missed by traditional screening.
• Your score is a relative measure (percentile), not a guarantee. Lifestyle and environment still play a major role.
• Current PRS are less accurate for non-European populations due to bias in the underlying research - a critical limitation being actively addressed.
• PRS works best combined with traditional risk factors, not as a replacement.
• If you've had DNA testing, upload your data to GenomeInsight to explore what your variants reveal about disease risk, drug metabolism, and more.

References

Choi, S. W., Mak, T. S.-H., & O'Reilly, P. F. (2020). Tutorial: a guide to performing polygenic risk score analyses. Nature Protocols, 15(9), 2759–2772. https://doi.org/10.1038/s41596-020-0353-1

Ding, Y., Hou, K., Xu, Z., Pimber, A., Beltran, E., Burch, K. S., ... & Pasaniuc, B. (2023). Polygenic scoring accuracy varies across the genetic ancestry continuum. Nature, 618, 774–781. https://doi.org/10.1038/s41586-023-06079-4

Khera, A. V., Chaffin, M., Aragam, K. G., Haas, M. E., Roselli, C., Choi, S. H., ... & Kathiresan, S. (2018). Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nature Genetics, 50(9), 1219–1224. https://doi.org/10.1038/s41588-018-0183-z

Khera, A. V., Emdin, C. A., Drake, I., Natarajan, P., Bick, A. G., Cook, N. R., ... & Kathiresan, S. (2019). Genetic risk, adherence to a healthy lifestyle, and coronary disease. New England Journal of Medicine, 375(24), 2349–2358. https://doi.org/10.1056/NEJMoa1605086

Lennon, N. J., Kottyan, L. C., Manolio, T. A., Murray, M. F., Schildcrout, J. S., Seto, T. B., ... & eMERGE Consortium. (2024). Selection, optimization and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse US populations. Nature Medicine, 30, 480–487. https://doi.org/10.1038/s41591-024-02796-z

Mars, N., Koskela, J. T., Ripatti, P., Kiiskinen, T., Havulinna, A. S., Lindbohm, J. V., ... & Ripatti, S. (2020). Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers. Nature Medicine, 26, 549–557. https://doi.org/10.1038/s41591-020-0800-0

Martin, A. R., Kanai, M., Kamatani, Y., Okada, Y., Neale, B. M., & Daly, M. J. (2019). Clinical use of current polygenic risk scores may exacerbate health disparities. Nature Genetics, 51, 584–591. https://doi.org/10.1038/s41588-019-0379-x

Mavaddat, N., Michailidou, K., Dennis, J., Lush, M., Fachal, L., Lee, A., ... & Easton, D. F. (2019). Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. American Journal of Human Genetics, 104(1), 21–34. https://doi.org/10.1016/j.ajhg.2018.11.002

Torkamani, A., Wineinger, N. E., & Topol, E. J. (2018). The personal and clinical utility of polygenic risk scores. Nature Reviews Genetics, 19, 581–590. https://doi.org/10.1038/s41576-018-0018-x

Uffelmann, E., Huang, Q. Q., Munung, N. S., de Vries, J., Okada, Y., Martin, A. R., ... & Posthuma, D. (2021). Genome-wide association studies. Nature Reviews Methods Primers, 1, 59. https://doi.org/10.1038/s43586-021-00056-9

Visscher, P. M., Wray, N. R., Zhang, Q., Sklar, P., McCarthy, M. I., Brown, M. A., & Yang, J. (2017). 10 years of GWAS discovery: biology, function, and translation. American Journal of Human Genetics, 101(1), 5–22. https://doi.org/10.1016/j.ajhg.2017.06.005

Wray, N. R., Lin, T., Austin, J., McGrath, J. J., Hickie, I. B., Murray, G. K., & Visscher, P. M. (2021). From basic science to clinical application of polygenic risk scores: a primer. JAMA Psychiatry, 78(1), 101–109. https://doi.org/10.1001/jamapsychiatry.2020.3049

Yengo, L., Vedantam, S., Marouli, E., Sidorenko, J., Bartell, E., Sakaue, S., ... & Visscher, P. M. (2022). A saturated map of common genetic variants associated with human height. Nature, 610, 704–712. https://doi.org/10.1038/s41586-022-05275-y

---

Related Reading

• heart disease genetic risk
• type 2 diabetes genetics
• benefits of genetic testing